Home » Stocks » Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. (ENTA)

Stock Price: $43.55 USD -1.18 (-2.64%)
Updated Oct 19, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 874.14M
Revenue (ttm) 150.16M
Net Income (ttm) 2.36M
Shares Out 20.07M
EPS (ttm) 0.12
PE Ratio 362.92
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $43.55
Previous Close $44.73
Change ($) -1.18
Change (%) -2.64%
Day's Open 44.77
Day's Range 43.07 - 44.99
Day's Volume 107,332
52-Week Range 38.40 - 67.88

More Stats

Market Cap 874.14M
Enterprise Value 512.34M
Earnings Date (est) Nov 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.07M
Float 17.74M
EPS (basic) 0.14
EPS (diluted) 0.12
FCF / Share 1.48
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.28%
FCF Yield 3.40%
Payout Ratio n/a
Shares Short 2.08M
Short Ratio 10.71
Short % of Float 11.74%
Beta 0.42
PE Ratio 362.92
Forward PE n/a
P/FCF Ratio 29.45
PS Ratio 5.82
PB Ratio 1.87
Revenue 150.16M
Operating Income -15.43M
Net Income 2.36M
Free Cash Flow 29.68M
Net Cash 361.80M
Net Cash / Share 18.02
Gross Margin 136.66%
Operating Margin -10.27%
Profit Margin 1.60%
FCF Margin 19.77%
ROA -1.96%
ROE 0.51%
ROIC -4.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 4
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$73.75*
(69.35% upside)
Low
45.0
Current: $43.55
High
117.0
Target: 73.75
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20520710388.2716147.7432.0541.7141.8822.76
Revenue Growth-0.69%100.97%16.48%-45.13%236.98%48.94%-23.15%-0.42%83.99%-
Gross Profit20520710388.2716147.7432.0541.7141.8822.76
Operating Income36.7488.3324.6130.8412418.999.0321.2925.306.94
Net Income46.3871.9617.7121.6778.9934.449.6321.4023.317.90
Shares Outstanding19.5819.2619.0718.9318.6718.369.791.091.121.13
Earnings Per Share2.213.480.911.134.091.80-0.671.131.320.18
EPS Growth-36.49%282.42%-19.47%-72.37%127.22%---14.39%633.33%-
Operating Cash Flow71.4229.2252.6535.8176.6720.1810.6522.6224.02-10.18
Capital Expenditures-5.42-2.98-2.51-4.74-2.34-1.03-0.61-0.19-0.44-0.04
Free Cash Flow66.0026.2450.1531.0774.3419.1510.0522.4423.58-10.21
Cash & Equivalents33630922421114691.2010244.2024.91-
Net Cash / Debt33630922421114691.2010244.2024.91-
Assets49041432728124615511752.1626.10-
Liabilities27.3420.5524.9611.349.866.766.518.234.14-
Book Value462394302270236149110-115-132-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enanta Pharmaceuticals, Inc.
Country United States
Employees 132
CEO Jay R. Luly

Stock Information

Ticker Symbol ENTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ENTA
IPO Date March 21, 2013

Description

Enanta Pharmaceuticals, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.